194 related articles for article (PubMed ID: 28551942)
1. [PROSTATE CANCER EARLY DETECTION USING PSA - CURRENT TRENDS AND RECENT UPDATES].
Lavi A; Cohen M
Harefuah; 2017 Mar; 156(3):185-188. PubMed ID: 28551942
[TBL] [Abstract][Full Text] [Related]
2. Screening: Actual trends on PSA marker. When, who, how?
Baccaglini W; Cathelineau X; Araújo Glina FP; Medina LG; Sotelo R; Carneiro A; Sanchez-Salas R
Arch Esp Urol; 2019 Mar; 72(2):98-103. PubMed ID: 30855010
[TBL] [Abstract][Full Text] [Related]
3. [PSA screening and molecular markers].
Lakes J; Arsov C
Urologe A; 2019 May; 58(5):486-493. PubMed ID: 30874831
[TBL] [Abstract][Full Text] [Related]
4. Prostate Cancer Screening and the Associated Controversy.
Tabayoyong W; Abouassaly R
Surg Clin North Am; 2015 Oct; 95(5):1023-39. PubMed ID: 26315521
[TBL] [Abstract][Full Text] [Related]
5. Early detection, PSA screening, and management of overdiagnosis.
Borza T; Konijeti R; Kibel AS
Hematol Oncol Clin North Am; 2013 Dec; 27(6):1091-110, vii. PubMed ID: 24188254
[TBL] [Abstract][Full Text] [Related]
6. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen screening, why have the guidelines changed?
Sountoulides P; Moutzouris G
Expert Rev Anticancer Ther; 2014 Nov; 14(11):1277-81. PubMed ID: 25306859
[TBL] [Abstract][Full Text] [Related]
8. Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later.
Pienta KJ
Urology; 2009 May; 73(5 Suppl):S11-20. PubMed ID: 19375622
[TBL] [Abstract][Full Text] [Related]
9. Cancer surveillance using registry data: Results and recommendations for the Lithuanian national prostate cancer early detection programme.
Gondos A; Krilaviciute A; Smailyte G; Ulys A; Brenner H
Eur J Cancer; 2015 Aug; 51(12):1630-7. PubMed ID: 26044924
[TBL] [Abstract][Full Text] [Related]
10. Screening for prostate cancer with PSA testing: current status and future directions.
Croswell JM; Kramer BS; Crawford ED
Oncology (Williston Park); 2011 May; 25(6):452-60, 463. PubMed ID: 21717898
[TBL] [Abstract][Full Text] [Related]
11. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.
Pron G
Ont Health Technol Assess Ser; 2015; 15(10):1-64. PubMed ID: 26366236
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.
van Leeuwen PJ; Connolly D; Gavin A; Roobol MJ; Black A; Bangma CH; Schröder FH
Eur J Cancer; 2010 Jan; 46(2):377-83. PubMed ID: 19804966
[TBL] [Abstract][Full Text] [Related]
13. Prostate-specific antigen: does the current evidence support its use in prostate cancer screening?
Duffy MJ
Ann Clin Biochem; 2011 Jul; 48(Pt 4):310-6. PubMed ID: 21525152
[TBL] [Abstract][Full Text] [Related]
14. PSA in screening for prostate cancer: more good than harm or more harm than good?
Duffy MJ
Adv Clin Chem; 2014; 66():1-23. PubMed ID: 25344984
[TBL] [Abstract][Full Text] [Related]
15. Applying strategies from libertarian paternalism to decision making for prostate specific antigen (PSA) screening.
Wheeler DC; Szymanski KM; Black A; Nelson DE
BMC Cancer; 2011 Apr; 11():148. PubMed ID: 21510865
[TBL] [Abstract][Full Text] [Related]
16. Prostate Cancer Screening.
Mulhem E; Fulbright N; Duncan N
Am Fam Physician; 2015 Oct; 92(8):683-8. PubMed ID: 26554408
[TBL] [Abstract][Full Text] [Related]
17. Overdiagnosis and overtreatment of prostate cancer.
Loeb S; Bjurlin MA; Nicholson J; Tammela TL; Penson DF; Carter HB; Carroll P; Etzioni R
Eur Urol; 2014 Jun; 65(6):1046-55. PubMed ID: 24439788
[TBL] [Abstract][Full Text] [Related]
18. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Fenton JJ; Weyrich MS; Durbin S; Liu Y; Bang H; Melnikow J
JAMA; 2018 May; 319(18):1914-1931. PubMed ID: 29801018
[TBL] [Abstract][Full Text] [Related]
19. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
[TBL] [Abstract][Full Text] [Related]
20. The prostate-specific antigen test.
Roobol MJ
Expert Opin Med Diagn; 2013 Sep; 7(5):423-6. PubMed ID: 23875974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]